TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has shared an announcement.
Botanix Pharmaceuticals Limited has successfully transitioned into a commercial revenue-generating company following the acquisition and FDA approval of its lead asset, Sofdra. The company reported significant growth in sales and revenue in its second full quarter post-launch, with a 50% increase in total prescriptions and a 65% rise in net revenue. The expansion of its sales force and the development of a differentiated fulfillment platform have been pivotal in driving this success, positioning Botanix strongly within the dermatology market.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a commercial dermatology company focused on developing and commercializing innovative dermatological products. The company’s primary product is Sofdra, an FDA-approved treatment for excessive underarm sweating. Botanix operates with a market focus on dermatology and has developed a proven fulfillment platform to support its commercial operations.
Average Trading Volume: 7,431,045
Technical Sentiment Signal: Sell
Current Market Cap: A$256.2M
Learn more about BOT stock on TipRanks’ Stock Analysis page.